Rodos BioTarget Overview

  • Founded
  • 2008
Founded
  • Status
  • Private
  • Employees
  • 2
Employees
  • Latest Deal Type
  • Bankr. Admin/​Reorg
  • Investors
  • 7

Rodos BioTarget General Information

Description

Developer of nanomedicine and nanoparticles designed to achieve enhanced prophylactic and therapeutic approaches against unmet medical needs. The company's nanoparticles can change the biodistribution and pharmacokinetics of the therapeutic cargos and protect them from the in vivo environment, thereby enabling physicians to improve the stability of the drug and enhance its target engagement.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Primary Office
  • Feodor-Lynen-Strasse 31
  • 30625 Hanover
  • Germany
+49 0511 00000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Rodos BioTarget Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Bankruptcy: Admin/Reorg 01-Aug-2021 Completed Generating Revenue
7. Later Stage VC 15-Jan-2020 00.000 00.000 000.00 Completed Generating Revenue
6. Grant 16-Oct-2017 00.000 00.000 Completed Generating Revenue
5. Later Stage VC 20-Aug-2017 00000 00.000 000.00 Completed Generating Revenue
4. Equity Crowdfunding 18-Aug-2017 00000 00.000 Completed Generating Revenue
3. Equity Crowdfunding 12-Nov-2016 00000 00.000 00.00 Completed Generating Revenue
2. Early Stage VC 01-Jan-2012 $3.41M $3.41M 000.00 Completed Generating Revenue
1. Seed Round 29-Apr-2009 Completed Startup
To view Rodos BioTarget’s complete valuation and funding history, request access »

Rodos BioTarget Patents

Rodos BioTarget Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-2995135-A1 Immunotherapies for malignant, neurodegenerative and demyelinating diseases by the use of targeted nanocarriers Abandoned 27-Jul-2015 00000000000
EP-3328367-A1 Immunotherapies for malignant, neurodegenerative and demyelinating diseases by the use of targeted nanocarriers Withdrawn 27-Jul-2015 00000000000
AU-2016298606-A1 Immunotherapies for malignant, neurodegenerative and demyelinating diseases by the use of targeted nanocarriers Abandoned 27-Jul-2015 00000000000
US-20180235992-A1 Immunotherapies for malignant, neurodegenerative and demyelinating diseases by the use of targeted nanocarriers Abandoned 27-Jul-2015 00000000000
US-20180140717-A1 Targeted nanocarriers for targeted drug delivery of gene therapeutics Pending 29-Apr-2015 A61K47/6913
To view Rodos BioTarget’s complete patent history, request access »

Rodos BioTarget Executive Team (5)

Name Title Board Seat Contact Info
Jörg Ruppert Ph.D Co-Founder & Chief Business Officer
Michael Scolaro MD Co-Founder & Medical Consultant
You’re viewing 2 of 5 executive team members. Get the full list »

Rodos BioTarget Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Rodos BioTarget Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
KEN (Private Equity & Venture Capital) Venture Capital Minority 000 0000 000000 0
Bundesministerium für Bildung und Forschung Government 000 0000 000000 0
Investitionsbank des Landes Brandenburg Investment Bank Minority 000 0000 000000 0
Otto Gies Angel (individual) Minority 000 0000 000000 0
KfW IPEX-Bank Investment Bank Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »